Stoke Therapeutics, Inc. (STOK) financial statements and ratios from SEC XBRL: revenue $-0.1B (TTM), net margin -3.7%, revenue growth 404.5% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $184.42M |
| Revenue (TTM) | $-0.1B |
| Net Margin | -3.7% |
| Operating Margin (TTM) | 311.0% |
| Revenue Growth (YoY) | 404.5% |
| EPS Growth (YoY) | -92.7% |
| FCF Growth (YoY) | -151.6% |
| Price / Book | 5.83 |
| Price / Sales | 62.10 |
| FCF Yield | -8.2% |
| Altman Z-Score | 16.71 (safe) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
STOK overview · STOK earnings · STOK KPIs · STOK documents · STOK ownership · STOK peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.